Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
life sciences
national blog main
national top stories
7
×
new york
7
×
new york blog main
new york top stories
boston top stories
clinical trials
amgen
inclisiran
regeneron pharmaceuticals
san francisco blog main
sanofi
alnylam pharmaceuticals
cholesterol
fda
pcsk9
pcsk9 inhibitors
praluent
repatha
san diego blog main
san diego top stories
san francisco top stories
the medicines co.
abbvie
acorda therapeutics
akcea therapeutics
akili interactive labs
alirocumab
allergan
ampyra
anylam pharmaceuticals
apokyn
apomorphine
biotech
bristol-myers squibb
bruce leuchter
cardiomyopathy
click therapeutics
What
drug
7
×
medicines
fda
approved
cholesterol
disease
medco
medicine
new
announced
lowering
meant
patients
twice
year
aces
acorda
acquire
ago
agreed
akcea
alnylam
amyloidosis
attr
available
backs
battle
bets
big
billion
bringing
brings
cash
ceo
clears
click
closer
company
compound
cope
Language
unset
Current search:
" new york "
×
drug
×
" national top stories "
×
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms
@xconomy.com
5 years ago
Sanofi Backs Click Therapeutics as Digital Medicines Gain Momentum